Pharming Group N.V. (PHAR) Earnings History
Annual and quarterly earnings data from 2005 to 2025
Loading earnings history...
PHAR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PHAR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 87.9% | 5.1% | 0.8% |
| 2024 | 88.1% | -2.9% | -4.0% |
| 2023 | 89.7% | -2.2% | -4.3% |
| 2022 | 91.5% | 8.9% | 6.7% |
| 2021 | 89.4% | 6.8% | 8.0% |
Download Data
Export PHAR earnings history in CSV or JSON format
Free sign-in required to download data
Pharming Group N.V. (PHAR) Earnings Overview
As of May 8, 2026, Pharming Group N.V. (PHAR) reported trailing twelve-month net income of $3M, reflecting +123.5% year-over-year growth. The company earned $0.04 per diluted share over the past four quarters, with a net profit margin of 0.8%.
Looking at the long-term picture, PHAR's 5-year EPS compound annual growth rate (CAGR) stands at -38.9%, signaling declining earnings. The company achieved its highest annual net income of $41M in fiscal 2019.
Pharming Group N.V. maintains positive profitability with a gross margin of 87.9%, operating margin of 5.1%, and net margin of 0.8%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including LGND ($49M net income, -2.4% margin), RARE (-$609M net income, -85.4% margin), ACAD ($376M net income, 36.5% margin), PHAR has outperformed on profitability metrics. Compare PHAR vs LGND →
PHAR Earnings vs Peers
Earnings metrics vs comparable public companies
PHAR Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3M | +124.1% | $19M | $0.04 | 0.8% | 5.1% |
| 2024 | -$12M | -12.3% | -$9M | $-0.17 | -4.0% | -2.9% |
| 2023 | -$11M | -177.1% | -$5M | $-0.14 | -4.3% | -2.2% |
| 2022 | $14M | -14.5% | $18M | $0.16 | 6.7% | 8.9% |
| 2021 | $16M | -57.6% | $14M | $0.18 | 8.0% | 6.8% |
| 2020 | $38M | -6.9% | $76M | $0.47 | 17.8% | 35.9% |
| 2019 | $41M | +41.9% | $68M | $0.48 | 21.4% | 36.0% |
| 2018 | $29M | +129.8% | $43M | $0.35 | 18.5% | 28.1% |
| 2017 | -$96M | -420.1% | $26M | $-1.54 | -89.2% | 24.4% |
| 2016 | -$18M | -69.4% | -$12M | $-0.35 | -110.5% | -72.7% |
See PHAR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PHAR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PHAR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPHAR — Frequently Asked Questions
Quick answers to the most common questions about buying PHAR stock.
Is PHAR growing earnings?
PHAR EPS is $0.04, with earnings growth accelerating to +123.5%. This exceeds the 5-year CAGR of -38.9%. TTM net income reached $3M.
What are PHAR's profit margins?
Pharming Group N.V. net margin is +0.8%, with operating margin at +5.1%. Below-average margins reflect competitive or cost pressures.
How consistent are PHAR's earnings?
PHAR earnings data spans 2005-2025. The accelerating earnings trend is +123.5% YoY. Historical data enables comparison across business cycles.